

C A R E B **Commodity Action Report & Eps Bulletin**

Recombinant Factor IX Products for the Treatment of Haemophilia B (NP35018)



Prepared by:

Hazel Johnstone
Commodity Manager
National Procurement

26 February 2019

Document Information

Contract Name: Recombinant Factor IX Products for the Treatment of Haemophilia B**Contract Reference:** NP35018**National Spend:** £4,111,658**Savings Opportunity:** £555,162**Start Date:** 1 March 2019**Expiry Date:** 28 February 2021**Contract Manager:** Hazel Johnstone, Commodity Manager**Tel :** GRO-C**Email:** Hazel.johnstone@GRO-C**Awarded Suppliers**

CSL Behring UK Ltd, Novo Nordisk Ltd, Pfizer Ltd, Shire Pharmaceuticals Ltd & Swedish Orphan Biovitrum (Sobi) Ltd

Key Strategy

Including NHS Scotland usage in a UK framework, led by the CMU, ensures that in a volume driven market the UK can access the lowest prices, thus giving NHS Scotland access to pricing that would otherwise be unachievable, while maximising efficiency by allowing PCF staff to concentrate on new areas of spend. Award framework for 24 months with the option to extend by up to 24 months.

Health Board	No Change Benefit	Comment
Ayrshire & Arran	£41,068	Haemophilia is a specialised service that is not available in all health boards. This area is managed via the National Services Division (NSD) risk-sharing arrangements on behalf of NHSS health boards.
Borders	£11,652	
Dumfries & Galloway	£16,440	
Fife	£37,845	This risk share scheme provides pooled funding for the provision of blood clotting concentrates for people with haemophilia and thrombophilia through the six haemophilia centres in Aberdeen, Dundee, Edinburgh, Glasgow, Inverness and the Royal Hospital for Children, Glasgow.
Forth Valley	£30,149	
Grampian	£54,845	
Greater Glasgow & Clyde	£123,855	In order to align with risk share scheme funding processes framework savings have been split across all boards based on NRAC.
Highland	£35,607	
Lanarkshire	£68,582	
Lothian	£82,546	The savings will be reviewed in consultation with NSD and health boards to support the delivery of the NSS Business Case during 2019/2020.
NWTC (Golden Jubilee)	-	
Orkney	£2,677	
Shetlands	£2,712	This document is for 'Information Only' to PCF SSGovernance, and is not intended to be distributed to Health Boards or uploaded to K-Hub.
Western Isles	£3,616	
Special HBs		
Tayside	£43,568	
Total	£555,162	

C A R E B National Procurement	RECOMBINANT FACTOR IX PRODUCTS FOR THE TREATMENT OF HAEMOPHILIA B	NP35018
--	--	----------------

Version on History

Version	Date	Revised By	Description	Filename
1.0	26 February 2019	Hazel Johnstone	C A R E B - Recombinant Factor IX	NP35018 CAREB rfIX V01.0 (Final)

Distribution

To	Action	Date
Head of Finance & Operations – Specialist & Screening Services	Cascade Distribution to appropriate users	26 February 2019
Dr. Campbell Tait (Consultant Haematologists – NHS GG&C)	Cascade Distribution to appropriate users	26 February 2019